---
title: "Jiuzhoutong (600998): Won the bid for the procurement project of Jingmen Maternal and Child Health Hospital, with a bid amount of 2.266 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287883943.md"
description: "JiuZhouTong (600998) won the bid for the procurement project of Jingmen Maternal and Child Health Hospital, with an amount of 2.266 million yuan. In 2025, the company's operating revenue is expected to be 161.39 billion yuan, with a net profit of 2.255 billion yuan. In the first quarter of 2026, the operating revenue is expected to be 44.783 billion yuan, with a net profit of 733 million yuan"
datetime: "2026-05-28T08:37:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287883943.md)
  - [en](https://longbridge.com/en/news/287883943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287883943.md)
---

# Jiuzhoutong (600998): Won the bid for the procurement project of Jingmen Maternal and Child Health Hospital, with a bid amount of 2.266 million yuan

According to Tongbi Finance, data from Qichacha shows that, based on the "Announcement of the Second Bid Results for the Procurement Project of Color Doppler Ultrasound Diagnostic Equipment by Jingmen Maternal and Child Health Hospital," JiuZhouTong Pharmaceutical Group Co., Ltd. announced on May 28, 2026, that it won the bid for the procurement project of Jingmen Maternal and Child Health Hospital, with a bid amount of 2.266 million yuan.

Related listed company: JiuZhouTong (600998.SH)

_Tongbi Finance Tip:_

_JiuZhouTong (600998.SH) reported an operating income of 161.39 billion yuan in 2025, with a revenue growth rate of 6.31%. The net profit attributable to the parent company was 2.255 billion yuan, with a net profit growth rate of -10.07%, and a return on equity of 8.29%._

_In the first quarter of 2026, the company's operating income was 44.783 billion yuan, with a revenue growth rate of 6.58%. The net profit attributable to the parent company was 733 million yuan, with a net profit growth rate of -24.41%._

_The company currently belongs to the healthcare industry, with the main product types being pharmaceutical distribution and professional consulting services. According to the 2025 annual report, the main business composition is as follows: commercial distribution business (excluding general agency sales and self-produced): 82.82%; general agency sales and self-produced business: 12.25%; pharmaceutical manufacturing and private label business: 2.07%; pharmaceutical retail: 1.78%; third-party logistics business: 0.8%; healthcare and technology services: 0.19%; other businesses: 0.09%._

## Related News & Research

- [Here’s how wages have grown in every state over 10 years](https://longbridge.com/en/news/289588648.md)
- [11:45 ETInventHelp Inventor Develops Temporarily Seal for a Leaking Pipe (OCC-1819)](https://longbridge.com/en/news/289489220.md)
- [Farmland: Iowa value study tracks historic price reversals](https://longbridge.com/en/news/289169687.md)
- [RA Capital-backed SPAC Research Alliance Corp. IV files for a $75 million IPO, targeting healthcare](https://longbridge.com/en/news/289107233.md)
- [Trump’s name removed from Kennedy Center website branding](https://longbridge.com/en/news/289101851.md)